About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Soricimed Biopharma Inc. Strengthens Executive Team with Appointment of Dr. Michael Groaning PhD, as Chief Scientific Officer

By: Newsfile

Moncton, New Brunswick and Boston, Massachusetts--(Newsfile Corp. - September 2, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on developing precision oncology drugs, today announced the appointment of Dr. Michael Groaning PhD, as Chief Scientific Officer (CSO). This strategic addition underscores Soricimed's commitment to advancing its TRPV6-targeting Radioligand Therapies (RLT) pipeline and driving long-term value for patients and stakeholders.

Dr. Groaning brings over 25 years of expertise in oncology and radiopharmaceutical development, with a distinguished track record spanning immunotherapy, chemotherapy, diagnostic innovation, and radioligand therapy. His leadership has been instrumental in the successful development and commercialization of novel cancer treatments.

Most recently, he served as Vice President, Global Program Leader at Fusion Pharmaceuticals/Astra Zeneca as the prostate cancer program thought leader and key advisor on radiopharmaceutical development. Prior to that, he played a pivotal role at Endocyte/Novartis in the design and execution of the VISION and PSMAfore clinical trials, which led to the regulatory approval of Pluvicto®, the first radioligand therapy for prostate cancer.

"Michael's appointment represents a significant milestone for Soricimed," said Paul Gunn, President of Soricimed Biopharma Inc. "His scientific acumen and operational leadership will be instrumental as we expand our precision oncology pipeline, advance clinical programs, and position the company for strategic partnerships and growth."

"Bringing Dr. Groaning on board reflects Soricimed's commitment to building a world-class leadership team," said Dr. Neil Fleshner, Executive Director. "His unparalleled expertise in radiopharmaceutical development and oncology drug innovation will be invaluable as we accelerate our TRPV6-targeted precision oncology programs and pursue new opportunities to bring transformative therapies to patients."

As CSO, Dr. Groaning will lead Soricimed's precision oncology drug research and development strategy, oversee preclinical and clinical programs—including its lead TRPV6-targeted RLT candidates—and support key initiatives aimed at maximizing shareholder value.

"I'm thrilled to join Soricimed at such a dynamic stage in its evolution," said Dr. Groaning. "The company's proprietary precision oncology program holds transformative potential for the treatment of solid tumor cancers. I look forward to driving innovation and helping unlock the full clinical and commercial impact of this technology."

Dr. Groaning holds a PhD in Organic Chemistry from the Colorado State University and A Master of Public Health in Epidemiology and Biostatistics from Tufts University School of Medicine. He has held senior leadership roles across several high-growth biotech and pharmaceutical firms.

His appointment comes at a pivotal time as Soricimed advances its Radioligand Therapy program, with lead candidate expected to complete Phase 0 clinical trials within the next 12-18 months. Dr. Groaning's deep experience and leadership in the development of Radioligand Therapies will be critical in guiding the company through key development milestones.

About Soricimed Biopharma Inc.

Soricimed Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted cancer therapeutics. Leveraging its proprietary peptide platform, Soricimed is advancing a portfolio of precision oncology drugs, including Radioligand Therapies, through Phase 0 clinical proof-of-concept studies. The company is also developing a suite of peptide-drug conjugates designed to deliver diverse anti-cancer payloads.

For media inquiries, please contact:

Paul Gunn
President and Director
pgunn@soricimed.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264676

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.